Pyrogallol Suppresses the Tumor Progression via Modulating Aerobic Glycolysis and STAT2 Signaling Pathway in Non-small Cell Lung Carcinoma

Background Pyrogallol, a bioactive compound derived from natural sources, is the focus of this study, aiming to investigate its anti-cancer properties against A549 lung cancer cells and uncover the underlying mechanisms. Purpose This study seeks to elucidate the therapeutic potential of pyrogallol as a novel anti-cancer agent for NSCLC by targeting aerobic glycolysis and signal transducer and activator of transcription 2 (STAT2) signaling pathway. Background Pyrogallol, a bioactive compound derived from natural sources, is the focus of this study, aiming to investigate its anti-cancer properties against A549 lung cancer cells and uncover the underlying mechanisms. Materials and Methods A range of pyrogallol doses was administered to A549 cells, followed by a comprehensive analysis utilizing bioinformatic tools like Gene Expression Omnibus (GEO), GEO2R, WebGestalt, and the Search Tool for Interactions of Chemicals database. Assessments of cytotoxicity were conducted using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and trypan blue assays post-treatment of A549 cells with pyrogallol. Cell cycle progression and cell death were evaluated via flow cytometry using Annexin V-fluorescein isothiocyanates/propidium iodide double staining. Network analysis helped identify pertinent signaling pathways, while RT-PCR validated mRNA expression changes in A549 cells. Auto dock docking studies were employed to gauge the binding affinity of pyrogallol with targets associated with the STAT2-mediated pathway. Results Pyrogallol notably impeded the progression of A549 cells by prompting cell cycle arrest in the G0/G1 phase and fostering apoptosis. Network analysis highlighted its role in regulating metabolism, apoptosis, and STAT2 targets linked to lung tumorigenesis. RT-PCR validation affirmed the downregulation of genes associated with cell cycle and apoptosis targets. Furthermore, docking studies indicated a robust binding affinity between pyrogallol and the signaling targets within the STAT2 pathway. Pyrogallol displays the potential to halt the growth of lung cancer cells, indicating its promise as a viable treatment for this condition. Conclusion These discoveries emphasize the need for additional research and clinical studies to fully harness its therapeutic benefits for lung cancer treatment.